Figure 6.

Co-treatment with ψ-GSH dipeptide (2, 250 mg/kg, i.p.) with glycine (250 mg/kg, i.p.) showed improved cognitive benefits over the treatment of compound 2 alone. (A) Impaired alternation in Aβ-injected mice was restored by compound 2 treatment and showed a trend toward further improvement in the co-treatment (2 + glycine) group. (B) Increased number of re-entries in the Aβ-only treated group was significantly reduced in the co-treatment of compound 2 + glycine group, compared to treatment of compound 2 alone. (C) The treatment group did not show any side preference during the conduction of this test. Data are shown as the mean ± SEM. Statistical significance was assessed by a one-way ANOVA with Tukey’s post-hoc test (ns = not significant, * p < 0.05, **** p < 0.001).